New Indication Approved for Juvéderm

In a randomized, controlled trial, 59% of adults reported experiencing at least one treatment site response.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-approves-new-indication-dermal-filler-2024a10004a9?src=rss